Headache CurrentsPub Date : 2009-05-12DOI: 10.1111/j.1743-5013.2006.00041.x-i1
Julio Pascual M.D., Ph.D.
{"title":"Current Preventive Therapy: What We Know About Mechanism(s) of Action?","authors":"Julio Pascual \u0000 M.D., Ph.D.","doi":"10.1111/j.1743-5013.2006.00041.x-i1","DOIUrl":"10.1111/j.1743-5013.2006.00041.x-i1","url":null,"abstract":"","PeriodicalId":100600,"journal":{"name":"Headache Currents","volume":"3 5","pages":"120-123"},"PeriodicalIF":0.0,"publicationDate":"2009-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1743-5013.2006.00041.x-i1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"93126619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Headache CurrentsPub Date : 2009-05-12DOI: 10.1111/j.1526-4610.2005.05063.x-i1
Lars Edvinsson M.D., Ph. D.
{"title":"Future Preventive Therapy: Are There Promising Drug Targets?","authors":"Lars Edvinsson M.D., Ph. D.","doi":"10.1111/j.1526-4610.2005.05063.x-i1","DOIUrl":"https://doi.org/10.1111/j.1526-4610.2005.05063.x-i1","url":null,"abstract":"<p> <i>The primary headaches are among the most prevalent neurological disorders, afflicting up to 16% in Europe and 22% in USA of the adult population. The associated pain originates from intracranial blood vessels that are innervated by sensory nerves storing several neurotransmitters. In primary headaches, there is a clear association between the headache and the release of calcitonin gene-related peptide (CGRP) but not with other neuronal messengers. The specific purpose of this review is to describe the various anatomical aspects of neurotransmitters and mechanisms in the human cranial circulation and to elucidate a possible role for a specific agonist/antagonist in the treatment of primary headaches. Some of the drugs have emerged from laboratory science in the last decade, but most by coincidence when treating other disorders. The difference between an acute or a prophylactic antimigraine medication may simply reśide in the fact that the former includes an acute vasoconstrictor ability and has a shorter receptor binding time.</i> </p>","PeriodicalId":100600,"journal":{"name":"Headache Currents","volume":"3 5","pages":"101-107"},"PeriodicalIF":0.0,"publicationDate":"2009-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1526-4610.2005.05063.x-i1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91829367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Headache CurrentsPub Date : 2009-05-12DOI: 10.1111/j.1743-5013.2006.00040.x-i1
Jean Schoenen M.D., Ph.D.
{"title":"Future Preventive Therapy: Are There Promising Drug Targets?","authors":"Jean Schoenen \u0000 M.D., Ph.D.","doi":"10.1111/j.1743-5013.2006.00040.x-i1","DOIUrl":"https://doi.org/10.1111/j.1743-5013.2006.00040.x-i1","url":null,"abstract":"","PeriodicalId":100600,"journal":{"name":"Headache Currents","volume":"3 5","pages":"108-111"},"PeriodicalIF":0.0,"publicationDate":"2009-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1743-5013.2006.00040.x-i1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91829368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Headache CurrentsPub Date : 2006-09-01DOI: 10.1111/J.1526-4610.2005.05063.X-I1
L. Edvinsson
{"title":"Future Preventive Therapy: Are There Promising Drug Targets?","authors":"L. Edvinsson","doi":"10.1111/J.1526-4610.2005.05063.X-I1","DOIUrl":"https://doi.org/10.1111/J.1526-4610.2005.05063.X-I1","url":null,"abstract":"The primary headaches are among the most prevalent neurological disorders, afflicting up to 16% in Europe and 22% in USA of the adult population. The associated pain originates from intracranial blood vessels that are innervated by sensory nerves storing several neurotransmitters. In primary headaches, there is a clear association between the headache and the release of calcitonin gene-related peptide (CGRP) but not with other neuronal messengers. The specific purpose of this review is to describe the various anatomical aspects of neurotransmitters and mechanisms in the human cranial circulation and to elucidate a possible role for a specific agonist/antagonist in the treatment of primary headaches. Some of the drugs have emerged from laboratory science in the last decade, but most by coincidence when treating other disorders. The difference between an acute or a prophylactic antimigraine medication may simply reśide in the fact that the former includes an acute vasoconstrictor ability and has a shorter receptor binding time.","PeriodicalId":100600,"journal":{"name":"Headache Currents","volume":"49 1","pages":"101-107"},"PeriodicalIF":0.0,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90649559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Headache CurrentsPub Date : 2006-09-01DOI: 10.1111/J.1743-5013.2006.00042.X
J. Schoenen
{"title":"Future Preventive Therapy: Are There Promising Drug Targets?","authors":"J. Schoenen","doi":"10.1111/J.1743-5013.2006.00042.X","DOIUrl":"https://doi.org/10.1111/J.1743-5013.2006.00042.X","url":null,"abstract":"","PeriodicalId":100600,"journal":{"name":"Headache Currents","volume":"42 1","pages":"108-111"},"PeriodicalIF":0.0,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88904178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Headache CurrentsPub Date : 2006-08-14DOI: 10.1111/j.1743-5013.2006.00039.x
Gisela M. Terwindt M.D., Ph.D. , Joost Haan M.D., Ph.D. , Michel D. Ferrari M.D., Ph.D.
{"title":"Hemiplegic and Basilar-type Migraine: Current and Future Treatment","authors":"Gisela M. Terwindt \u0000 M.D., Ph.D.\u0000 , Joost Haan \u0000 M.D., Ph.D.\u0000 , Michel D. Ferrari \u0000 M.D., Ph.D.","doi":"10.1111/j.1743-5013.2006.00039.x","DOIUrl":"10.1111/j.1743-5013.2006.00039.x","url":null,"abstract":"","PeriodicalId":100600,"journal":{"name":"Headache Currents","volume":"3 4","pages":"97-100"},"PeriodicalIF":0.0,"publicationDate":"2006-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1743-5013.2006.00039.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79304236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Headache CurrentsPub Date : 2006-08-14DOI: 10.1111/j.1743-5013.2006.00036.x
Esther De Theije-Kors M.D., Ph.D., Joost Haan M.D., Ph.D.
{"title":"Hemiplegic and Basilar-type Migraine: Epidemiology, Genetics, and Mechanisms","authors":"Esther De Theije-Kors M.D., Ph.D., Joost Haan M.D., Ph.D.","doi":"10.1111/j.1743-5013.2006.00036.x","DOIUrl":"https://doi.org/10.1111/j.1743-5013.2006.00036.x","url":null,"abstract":"<p> <i>Migraine is a frequent primary paroxysmal headache disorder. Within the migraine spectrum, rare variants can be recognized, such as hemiplegic migraine and basilar-type migraine. Hemiplegic migraine can occur sporadically or run in families with an autosomal dominant inheritance pattern. Genetic research in familial hemiplegic migraine has led to the identification of three genes so far. The CACNA1A gene is associated with the FHM1 phenotype, the ATP1A2 gene with FHM2, and the SCN1A gene with FHM3. A large phenotypic variety is seen, without a clear genotype-phenotype relation. While additional cerebellar ataxia predominantly is associated with the FHM1 phenotype, all three are associated with epileptic phenomena. Mutated genes in all three types of FHM are important in ion transport, defining FHM—and probably migraine in general—as an “ionopathy.” Functional studies of FHM1, FHM2, and FHM3 link the effects to the initiation of cortical spreading depression. With the identification of the three genetic subtypes of FHM, confirmation of a migraine diagnosis by molecular tests has become available.</i> </p>","PeriodicalId":100600,"journal":{"name":"Headache Currents","volume":"3 4","pages":"73-81"},"PeriodicalIF":0.0,"publicationDate":"2006-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1743-5013.2006.00036.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91833651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}